title: Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study.
abstract: BACKGROUND
  The aim of this study was to compare the effect of combination lamivudine (LAM) and adefovir dipivoxil (ADV) versus entecavir (ETV) monotherapy for naïve HBeAg-positive chronic hepatitis B (CHB) patients.
  
  
  METHODS
  Fifty enrolled patients with CHB were evenly divided into 2 groups: a group treated with of lamivudine (LAM) (100 mg/day) plus adefovir (ADV) (10 mg/day) combination, and a group treated with entecavir (ETV) (0.5 mg/day). Serum levels of ALT, AST, creatinine, bilirubin, HBsAg, HBeAg and HBV viral load, and genotypic resistance were analyzed at 0, 12, 24, 52, and 104 weeks. HBV DNA levels were determined by real-time PCR and HBsAg and HBeAg by chemiluminescence. Serum levels of ALT, AST, creatinine, and bilirubin were measured by an automatic biochemical analyzer. Data analysis was performed with SPSS 12.0 software.
  
  
  RESULTS
  There were no significant differences in the virological response (VR) rates between LAM+ADV and ETV cohorts at 24, 52, and 104 weeks (P>0.05). The HBeAg seroconversion rates were 28% and 20%, and the biochemical response (BR) rates were 88% and 84% at week 104 in the LAM+ADV and ETV groups, respectively. The rates of undetectable HBV DNA, HBeAg seroconversion, and ALT normalization rates were similar in both cohorts. No virological breakthrough or serious adverse effects were noted for any patient during the study period.
  
  
  CONCLUSIONS
  Both LAM+ADV combination therapy and ETV monotherapy were effective and safe in the treatment of -naïve HBeAg-positive CHB patients. However, further studies are needed to obtain long-term results.
authors.affiliation: Department of Infectious Diseases, Third Affiliated Hospital to Wenzhou Medical College, Ruian, Zhejiang, P.R. China.
authors.forename: Qing-Wei
authors.initials: QW
authors.lastname: Du
authors.forename: Ji-Guang
authors.initials: JG
authors.lastname: Ding
authors.forename: Qing-Feng
authors.initials: QF
authors.lastname: Sun
authors.forename: Liang
authors.initials: L
authors.lastname: Hong
authors.forename: Fu-Jing
authors.initials: FJ
authors.lastname: Cai
authors.forename: Qing-Qing
authors.initials: QQ
authors.lastname: Zhou
authors.forename: Yang-He
authors.initials: YH
authors.lastname: Wu
authors.forename: Rong-Quan
authors.initials: RQ
authors.lastname: Fu
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000704:Analysis of Variance; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000378:metabolism; D004338:Drug Combinations; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D010865:Pilot Projects
chemical_list: D004338:Drug Combinations; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D063065:Organophosphonates; D019259:Lamivudine; C413685:entecavir; D006147:Guanine; C053001:adefovir; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000225:Adenine; D001663:Bilirubin
references.citation: Intervirology. 2008;51(6):385-93
references.pmid: 19229115
references.citation: J Gastroenterol Hepatol. 2009 Aug;24(8):1417-23
references.pmid: 19486254
references.citation: Gastroenterology. 2004 Jan;126(1):91-101
references.pmid: 14699491
references.citation: World J Gastroenterol. 2011 Nov 21;17(43):4804-9
references.pmid: 22147982
references.citation: Curr Opin Gastroenterol. 2009 May;25(3):180-5
references.pmid: 19387254
references.citation: Hepatol Res. 2011 May;41(5):405-16
references.pmid: 21435126
references.citation: Hepatology. 2002 Jul;36(1):219-26
references.pmid: 12085368
references.citation: Virol J. 2011 Aug 04;8:388
references.pmid: 21816062
references.citation: J Med Virol. 2008 Jul;80(7):1160-70
references.pmid: 18461609
references.citation: Curr Opin Virol. 2012 Aug;2(4):467-73
references.pmid: 22722078
references.citation: N Engl J Med. 2006 Mar 9;354(10):1011-20
references.pmid: 16525138
references.citation: Gastroenterology. 2011 Oct;141(4):1240-8, 1248.e1-2
references.pmid: 21703214
references.citation: Hepatology. 2004 Oct;40(4):883-91
references.pmid: 15382125
references.citation: Hepatol Int. 2011 Jun;5(2):671-6
references.pmid: 21484140
references.citation: Hepatology. 2000 Nov;32(5):1145-53
references.pmid: 11050068
references.citation: Gastroenterology. 2011 Jan;140(1):132-43
references.pmid: 20955704
references.citation: J Med Virol. 2012 Mar;84(3):424-30
references.pmid: 22246827
references.citation: N Engl J Med. 2006 Mar 9;354(10):1001-10
references.pmid: 16525137
references.citation: Gastroenterology. 2004 Jan;126(1):81-90
references.pmid: 14699490
references.citation: Future Microbiol. 2008 Oct;3(5):525-38
references.pmid: 18811237
references.citation: Eur J Gastroenterol Hepatol. 2012 May;24(5):535-42
references.pmid: 22382708
references.citation: Hepatology. 2008 Sep;48(3):750-8
references.pmid: 18752330
references.citation: Med Sci Monit. 2012 Dec;18(12):CR698-705
references.pmid: 23197230
references.citation: Minerva Gastroenterol Dietol. 2009 Mar;55(1):5-22
references.pmid: 19212304
references.citation: Virol J. 2009 Oct 09;6:163
references.pmid: 19818142
references.citation: Hepatology. 2000 Oct;32(4 Pt 1):847-51
references.pmid: 11003633
references.citation: N Engl J Med. 2008 Dec 4;359(23):2442-55
references.pmid: 19052126
references.citation: J Hepatol. 1999 Mar;30(3):551
references.pmid: 10190743
references.citation: J Hepatol. 2011 Feb;54(2):236-42
references.pmid: 21030105